Key Highlights

  • Net loss was USD 86.1 million, compared with USD 71.1 million a year earlier.
  • Research and development expense rose 21% to USD 71.8 million on clinical trial activity.
  • Clinical expense reached USD 42.6 million, up 42% from USD 30.0 million.
  • Cash, equivalents and marketable securities totaled USD 461.7 million at September 30, 2026.

Eikon Therapeutics (NASDAQ:EIKN) reported a third-quarter 2026 loss per share of USD 1.59, against an estimate of a loss of USD 1.70. The company reported no revenue, and its net loss and comprehensive loss was USD 86.1 million, compared with USD 71.1 million in the third quarter of 2025.

Eikon describes itself as a late-stage clinical biopharmaceutical company building a global, integrated organization to develop medicines for serious unmet medical needs. Its approach combines traditional biology research with advanced engineering.

Operating Expenses and Net Loss

Research and development expense was USD 71.8 million, up USD 12.5 million, or 21%, from USD 59.3 million. Direct Research and Development expense rose USD 9.2 million and compensation costs rose USD 3.0 million as the company advanced clinical trial activity and the headcount that supports it.

Within research and development, clinical expense was USD 42.6 million, up 42%, while research and engineering expense was USD 29.3 million, essentially unchanged from USD 29.3 million. There was no in-process research and development expense in the quarter.

General and administrative expense was USD 18.7 million, up 21% from USD 15.4 million. Total operating expenses were USD 90.6 million against USD 74.8 million, and the loss from operations matched that figure. Net interest income was USD 4.5 million, up from USD 3.6 million.

For the nine months, research and development expense was USD 217.3 million against USD 185.1 million, general and administrative expense was USD 54.0 million against USD 70.7 million, and the net loss was USD 257.5 million against USD 244.6 million. In-process research and development was USD 5.0 million against USD 2.5 million.

Funding and Cash Position

Since inception, Eikon has funded operations mainly through sales of redeemable convertible preferred stock and, more recently, its initial public offering. On February 6, 2026, it closed the offering and issued 21,177,600 shares of common stock at USD 18.00 per share.

At September 30, 2026, the company held USD 461.7 million in cash, cash equivalents and marketable securities. It has not generated Revenue from product sales and has reported significant annual operating losses and negative operating cash flows since inception.

The filing groups its research and development expenses into research and engineering, clinical and in-process research and development categories. For the nine months, clinical expense was USD 123.8 million against USD 83.1 million, while research and engineering expense was USD 88.5 million against USD 99.5 million.

Reported Line Items to Reference

The income statement shows two Operating Expense lines, research and development and general and administrative. Of the research and development total, clinical expense is the line that grew most, with research and engineering unchanged from a year earlier.

The Balance Sheet figure of USD 461.7 million in cash, equivalents and marketable securities is the Liquidity measure in the filing, and the February 2026 offering is the funding event it describes. The company reports no revenue for either period.